Tizona Therapeutics is a US immuno-oncology company. In 2019, Abbvie purchased an option to in-license Tizona’s most advanced clinical program for certain payments. This program has now been spun out into Trishula Therapeutics which has entered phase 2 development in pancreatic cancer. In 2020, Gilead purchased an option to acquire the remainder of Tizona for certain payments including $300M upfront. Gilead recently declined to option and Tizona is seeking alternative options for further development.